USPTO serial 78883882
TRIGEN ADVANCING CARDIOVASCULAR CARE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- DINALLO, KEVIN M
- Law office
- TMEG LAW OFFICE 107 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with TRIGEN ADVANCING CARDIOVASCULAR CARE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lisa M. Caldwell
LISA M CALDWELL KLARQUIST SPARKMAN LLPONE WORLD TRADE CTR121 SW SALMON ST STE 1600PORTLAND, OR 97204Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Scientific research for medical purposes; drug discovery and drug development services, consultancy services relating to the discovery, development and evaluation of drugs, technical support services, all provided by a pharmaceutical research and/or development company; research and development services to find and develop new pharmaceutical products for others to put on the market; pharmaceutical research services; pharmaceutical research services enabling others to acquire licences or other rights relating to the results or benefits, including candidate pharmaceutical products, arising from the research; arranging investigations and/or research to obtain information and/or data, to be supplied to others, relating to drugs, formulations and/or candidate pharmaceutical products; preparing or arranging the preparation of chemicals, biological products, formulations and/or candidate pharmaceutical products to enable others to acquire information, data and/or rights relating to the preparative techniques and/or prepared products; the provision of reports and information relating to chemicals, biological products, the preparation of either, formulations, candidate pharmaceutical products, pharmaceutical or medical research projects, pharmaceutical or medical research services, medicine, chemistry, molecular biology, disease and/property rights; the obtainment and compilation, for the benefit of others, of information, data and/or documents relating to candidate pharmaceutical products, enabling prospective business partners, licensees and/or assignees to assess the information, data and/or documents; acquiring or arranging the acquisition of intellectual property rights (including the preparation, filing and prosecution of patent applications), to enable others to licence-in or buy-in the rights; licensing of intellectual property rights; assigning intellectual property rights; provision on the Internet of documents and information relating to chemicals, biological molecules, the preparation of either, pharmaceutical agents, pharmaceutical formulations, candidate pharmaceutical products, pharmaceutical or medical research project, pharmaceutical or medical research services, chemistry, molecular biology, disease and/or intellectual property rights; scientific and pharmaceutical research services relating to blood clotting and/or thrombosis and to substances for use in controlling blood clotting or for the treatment or prevention of thrombosis; provision of information relating to research and development activities concerning blood clotting, thrombosis, and/or substances for use in controlling blood clotting or for the treatment or prevention of thrombosis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 8, 2009 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Dec 8, 2009 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 12, 2009 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 12, 2009 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 12, 2009 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 21, 2009 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Apr 21, 2009 | ALIE | ASSIGNED TO LIE | — |
| Oct 17, 2008 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Oct 17, 2008 | ALIE | ASSIGNED TO LIE | — |
| Apr 17, 2008 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Oct 17, 2007 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Apr 6, 2007 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Apr 6, 2007 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Mar 30, 2007 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Mar 30, 2007 | ALIE | ASSIGNED TO LIE | — |
| Feb 23, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 23, 2007 | PAPER RECEIVED | — | |
| Aug 24, 2006 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 24, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 24, 2006 | DOCK | ASSIGNED TO EXAMINER | — |
| May 20, 2006 | MDSC | NOTICE OF DESIGN SEARCH CODE MAILED | — |
| May 19, 2006 | NWAP | NEW APPLICATION ENTERED | — |